You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Apidra Articles
Popular Apidra Articles
Highly Recommended Apidra Articles
Send a link to this page to your friends and colleagues.
This press release is an announcement submitted by Sanofi-aventis, and was not written by Diabetes Health.
At the recent 44th annual meeting of the European Association for the Study of Diabetes (EASD), sanofi-aventis announced a study demonstrating that a basal-bolus insulin regimen with Lantus® once daily (basal insulin) and rapid-acting Apidra® (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) resulted in significant A1c reductions from baseline as compared to pre-mixed insulin in people with type 2 diabetes.
In the GINGER study, the overall A1c change from baseline to endpoint with Lantus and Apidra was 1.3% versus 0.8% with pre-mix. The number of patients who reached an A1c of less than 7.0% at endpoint was significantly higher with Lantus and Apidra when compared to pre-mixed insulin.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.